Monash Haematology is a lead international site for expertise and clinical trial activity in lymphoid cancer and chronic myeloid disorders lead by Associate Prof Stephen Opat. Recent highlights include a lead role in GCLLSG CLL11, presented in the ASH plenary with authorship in the NEJM (2014; 370: 1101-10); the results of this trial represent a paradigm shift in chronic lymphocytic leukaemia.
Dr George Grigoriadis and Associate Prof Jake Shortt (JS) Monash Health are both recipients of VCA Clinical Research Fellowships and NHMRC Project Grants with strong translational work as part of the CCR at Hudson Institute of Medical Research and School of Clinical Sciences at Monash Health. Dr.Grigoriadis’s laboratory-based research focuses on myelodysplastic syndrome from low-to-high risk and impact on therapeutic approaches.
Associate Prof Shortt is the inaugural recipient of the Snowdome Foundation / VCA grant for ‘New targets in haematological malignancy’. His research expertise is in molecular mechanisms of cancer cell survival and targeted therapies including epigenetic and immunomodulatory approaches. In conjunction with NHMRC project grant funding he is conducting a phase I study an immunomodulatory epigenetic fragment (N-methyl-2-pyrrolidone; NMP) in relapsed and refractory multiple myeloma. Through the VEG, Dr Shortt will also be driving studies of epigenetic therapies in myeloma and lymphoma at the Monash Health Translational Precinct and collaborating centres.
Further information: Associate Professor Shortt Research Activities
Further information: Dr Grigoriadis Research Activities
Further information on haematology Clinical Trials: Clinical Haematology